NSE: APLLTD | BSE: 533573

Slowing Down Stock

Download real time

655.45 -20.85 (-3.08%)

New 52W Low today

54,061 NSE+BSE Volume

NSE 19 Mar, 2026 3:46 PM (IST)

12,883.7

Market Cap

High in industry

Beta 1Year

Very Low volatility

Alembic Pharmaceuticals Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for APLLTD, BSE:533573 Alembic Pharmaceuticals Ltd.

Search Inside the pdf :

Alembic Pharmaceuticals Ltd.

05 Feb 2026

655.45

-3.08%

Ex-US and Animal Health perform, while DF and US lag

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) exhibited in-line revenue with a slight miss on EBITDA/PAT for the quarter. While ex-US export growth was strong for the quarter, it was offset by moderate YoY growth in domestic formulation (DF) and US sales.

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

05 Nov 2025

655.45

-3.08%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharma is expected to maintain steady growth momentum supported by its expanding complex generics portfolio in the US, sustained traction in Ex-US markets, and a gradual recovery in the domestic formulations business.

Alembic Pharmaceutic.. has an average target of 1022.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

05 Nov 2025

655.45

-3.08%

Export drives the show; India outlook cloudy

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q2FY26 result beat our expectations – led by formulations exports (up 25.1% YoY) while India continued to grow at a modest pace (4.9% in Q2FY26).

Alembic Pharma has lost -22.73% in the last 3 Months

Alembic Pharmaceuticals Ltd.

05 Nov 2025

655.45

-3.08%

Alembic Pharma (BUY): All-round beat, US branded product entry to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Sales/EBITDA /PAT reported 7%/4%/8% above our estimates. EBITDA margin was marginally 50 bps below our estimates

Alembic Pharma has lost -15.46% in the last 1 Month

Alembic Pharmaceuticals Ltd.

05 Nov 2025

655.45

-3.08%

Strong Q2FY26 performance driven by US generics, margin expansion, and broad-based growth momentum

Buy: Alembic Pharmaceuticals Ltd.

Recommendation Target

Deven Choksey

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

12 Aug 2025

655.45

-3.08%

Steady Q1FY26 performance with positive FY26E outlook

Accumulate: Alembic Pharmaceuticals Ltd.

Deven Choksey

We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.

Alembic Pharmaceutic.. has an average target of 1022.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

06 Aug 2025

655.45

-3.08%

ERRATA: Alembic Pharma (BUY): Strong product mix to drive margins

Buy: Alembic Pharmaceuticals Ltd.

Target

BOB Capital Markets Ltd.

Earnings reported in-line where sales/EBITDA/PAT were -2.6/3.4%/-0.7% above estimates. EBITDA margin was 90 bps above estimates

Alembic Pharmaceuticals Ltd. is trading below all available SMAs

Alembic Pharmaceuticals Ltd.

06 Aug 2025

655.45

-3.08%

Turnaround in US growth; tepid traction in India

Hold: Alembic Pharmaceuticals Ltd.

Target

ICICI Securities Limited

Alembic Pharma’s (Alembic) Q1FY26 result was in line with our expectations. Revenue growth was mainly driven by US (13% YoY) and ex-US international business (21% YoY). India growth was tepid at 4.7% YoY due to challenges in specialty portfolio (up 1% YoY) and slowdown in acute market.

Alembic Pharmaceutic.. has an average target of 1022.00 from 4 brokers.

Alembic Pharmaceuticals Ltd.

05 Aug 2025

655.45

-3.08%

Export strength offsets muted DF/API show

Neutral: Alembic Pharmaceuticals Ltd.

Target

Motilal Oswal

Alembic Pharma (ALPM) delivered a largely in-line performance for 1QFY26. Superior execution in the export market led to YoY growth in revenue/EBITDA/PAT for the quarter.